Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions

Journal of Clinical Oncology

Volumn 15, Issue 9, 1997, Pages 3121-3128

  Fetell, Michael R ^a   Grossman, Stuart A ^a   Fisher, Joy D ^a   Erlanger, Bernard ^a   Rowinsky, Eric ^a   Stockel, John ^a   Piantadosi, Steven ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; PACLITAXEL; PROCARBAZINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG PENETRATION; ENZYME INDUCTION; FEMALE; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0030762796     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.9.3121     Document Type: Article

References (31)

1. Tishler RB, Geard CR, Hall EJ, Schiff PB: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495-3497, 1992
2. Tishler RB, Schiff PB, Geard CR, Hall EJ: Taxol: A novel radiation sensitizer. Int J Radiation Oncol Biol Phys 22:613-617, 1992
3. Prados MD, Schold SC, Spence AM, et al: Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14:2316-2321, 1996
4. Chamberlain MC, Kormanik P: Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13:2066-2071, 1995
5. Glantz MJ, Choy H, Kearns CM, et al: Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14:600-609, 1996
6. Lopes NM, Adams EG, Pitts TW, et al: Cell kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
7. Cahan MA, Walter KA, Colvin OM, Brem H: Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33:441-444, 1994
8. Ettinger DS: Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come. J Clin Oncol 8:374-377, 1990
9. Finlay JL, Geyer JR, Turski PA, et al: Pre-irradiation chemotherapy in children with high-grade astrocytoma: Tumor response to two cycles of the "8-drugs-in-1-day" regimen. A Children's Cancer Group study. J Neuro-Oncol 21:255-265, 1994
10. Grossraan SA, Wharam M, Sheidler VR, et al: Phase II study of continuous infusion BCNU and cisplatin followed by cranial irradiation in adults with newly diagnosed high grade astrocytomas. J Clin Oncol, 1997 (in press)
11. Leu J-G, Jech KS, Wheeler NC, et al: Immunoassay of taxol and taxol-like compounds in plant extracts. Life Sciences 53:183-187, 1993
12. Leu J-G, Chen B-X, Schiff PB, Erlanger BF: Characterization of polyclonal and monoclonal anti-taxol antibodies and measurement of taxol in serum. Cancer Res 53:1388-1391, 1993
13. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
14. Fetell MR, Grossman SA, Balmaceda C, et al: Clinical and pharmacologic study of preirradiation taxol administered as a 96 hour infusion in adults with newly diagnosed glioblastoma multiform. Proc Am Soc Clin Oncol 13:179, 1994
15. Harris JW, Rahman A, Kim B-R, et al: Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome p450 3A4 and an unknown p450 enzyme. Cancer Res 54:4026-4035, 1994
16. Cresteil T, Monsarrat B, Alvinerie P, et al: Taxol metabolism by human microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 386-392, 1993
17. Eiseman JL, Eddington ND, Leslie J, et al: Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465-471, 1994
18. 3-H]-paclitaxel in rats: A quantitative autoradiographic study. Cancer Chemother Pharmacol 37:173-178, 1995
19. Heimans JJ, Vermorken JB, Wolbers JG, et al: Paclitaxel (taxol) concentrations in brain tumor tissue. Annals Oncol 5:951-953, 1994
20. Heimans JJ, Taphoorn MJ, Vermorken JB, et al: Does paclitaxel penetrate into brain tumor tissue? [letter]. J Natl Cancer Instit 87:1804-1805, 1995
21. Fung L, Ewend M, Sills A, et al: Polymer delivery of carmustine and 4-hydroxycyclophosphamide and taxol in the monkey brain. Proc Am Assoc Cancer Res 37:376, 1996
22. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013-2021, 1994
23. Curran WJ Jr, Scott CB, Horton J, et al: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials [see comments]. J Natl Cancer Instit 85:704-710, 1993
24. Wilson WH, Kang YK, Bryant G, et al: Phase I/II study of 96 hour infusional taxol in refractory lymphomas and breast cancer. Second National NCI Workshop on Taxol and Taxus, 1992
25. Wilson WH, Chabner BA, Bryant G, et al: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13:381-386, 1995
26. Chang S, Schold C, Spence A, et al: Phase I/II study of paclitaxel chemotherapy for recurrent malignant glioma: Preliminary report. North American Brain Tumor Consortium. Proc Am Soc Clin Oncol 15:153, 1996
27. Rowinsky EK: Clinical pharmacology of taxol. Monogr Natl Cancer Inst 15:25-37, 1993
28. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
29. Holmes F, Madden T, Newman R: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 9:1692-1703, 1996
30. Klaassen CD, Amdur MO, Doull J (eds): Casarett and Doull's Toxicology: The Basic Science of Poisons (ed 5). New York, NY, McGraw-Hill, 1996
31. Grossman SA, Hochberg F, Fisher J, et al for the NABTT CNS Consortium: Increased 9-aminocamptothecin (9-AC) dose requirements in patients on anticonvulsants. Proc Am Soc Clin Oncol 16:387, 1997